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Abstract The in vivo roles of meprin metalloproteases in
pathophysiological conditions remain elusive. Substrates
define protease roles. Therefore, to identify natural substrates
for human meprin a and b we employed TAILS (terminal
amine isotopic labeling of substrates), a proteomics approach
that enriches for N-terminal peptides of proteins and cleav-
age fragments. Of the 151 new extracellular substrates we
identified, it was notable that ADAM10 (a disintegrin and
metalloprotease domain-containing protein 10)—the consti-
tutive a-secretase—is activated by meprin b through
cleavage of the propeptide. To validate this cleavage event,
we expressed recombinant proADAM10 and after preincu-
bation with meprin b, this resulted in significantly elevated
ADAM10 activity. Cellular expression in murine primary
fibroblasts confirmed activation. Other novel substrates
including extracellular matrix proteins, growth factors and
inhibitors were validated by western analyses and enzyme
activity assays with Edman sequencing confirming the exact
cleavage sites identified by TAILS. Cleavages in vivo were
confirmed by comparing wild-type and meprin-/- mice. Our
finding of cystatin C, elafin and fetuin-A as substrates and
natural inhibitors for meprins reveal new mechanisms in the
regulation of protease activity important for understanding
pathophysiological processes.
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Introduction
Among proteases, the meprin a and b metalloproteases
show a unique structure and specificity. Meprin a is the
largest extracellular secreted protease, building chain and
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ring-like structures up to 6 MDa in size [1, 2]. In com-
parison, meprin b is a membrane-bound dimer, but can be
released from the cell surface by shedding [3]. However,
like many proteases, their in vivo roles remain unclear
through lack of understanding of their substrate repertoires,
also known as the substrate degradome [4]. Meprins have
been implicated in connective tissue formation, angiogen-
esis and immunology, but like many proteases, they are
also potentially important in pathologies. Thus, meprins are
associated with inflammatory bowel disease, kidney
nephritis, fibrosis and cancer [5–7], but their substrates and
roles in these diseases remain unclear.
To date meprin metalloproteases have been shown to
hydrolyze a number of different proteins in vitro [8], but
only a few in vivo substrates have been identified, such as
interleukin-1b [9], interleukin-18 (IL-18) [10], transform-
ing growth factor a (TGF-a) [11] and vascular endothelial
growth factor A (VEGF-A) [12]. Recently, high-through-
put approaches involving protease proteomics (also known
as degradomics) have been applied to meprins. Proteomic
identification of cleavage site specificity [13] shows that
meprins preferentially cleave N-terminal to the acidic
amino acids glutamate and aspartate [14]. Indeed, this is
concordant with most of the few known substrates. For
example, procollagen III is processed by meprin a and b at
an aspartate in P10, releasing the mature triple helical
collagen, which then further assembles to form collagen
fibrils [15]. Meprin b specifically cleaves in the N-terminal
region of the amyloid precursor protein (APP), again at
negatively charged amino acid residues [16], releasing two
peptides that have been identified in the brain cerebrospinal
fluid of patients with Alzheimer’s disease [17]. While this
implicates meprin b in neurological pathophysiology, the
lack of known substrates reveals yawning gaps in mecha-
nistic information on meprin function in vivo.
Proteases rarely act alone. Instead, many form activation
networks or cascades [18–20]. Indeed, it has been suggested
that proteases form a deeply interconnected protease web
embedded in every tissue proteome [21–24]. In this network,
inhibitors are important control points in proteolytic signal-
ing, such as the tissue inhibitors of matrix metalloproteases
(TIMPs) 1–4 for MMPs and TIMP3 for ADAMs (a disinte-
grin and metalloprotease domain-containing protein), yet no
specific natural inhibitors have been identified for the mep-
rins. In another prominent example, the serine protease
inhibitor lymphoepithelial Kazal-type-related inhibitor
(LEKTI) has a crucial impact on the homeostasis of epider-
mal skin as shown from mutations in the cognate SPINK5
gene. Such mutations result in nonfunctional LEKTI inca-
pable of blocking kallikreins (KLK) and KLK-related
peptidases, so leading to severe defects in skin desquamation
in Netherton syndrome mediated by hyperactivity of KLK-
related peptidases [25]. In the protease web, protease inhib-
itors can be inactivated by proteolytic activity from other
classes of proteases. For example, the cysteine protease
inhibitor cystatin C is cleaved and inactivated by MMPs
leading to increased cathepsin L activity [26].
Another family of metalloproteases, the ADAMs, are cell
surface proteases often involved in protein shedding from
the plasma membrane [20, 27]. ADAM10 is important for
the development of blood vessels and the central nervous
system, as well as in pathological conditions such as
inflammation and cancer [28, 29]. Recently, it was shown
that ADAM10 is the major sheddase of notch receptors,
involved in the release of the extracellular domain and so
mediating skin development [30]. As the constitutive
a-secretase of amyloid protein [31, 32], ADAM10 is presumed
to prevent the formation of aggregates of neurodegenerative
amyloid b peptides derived from the amyloid precursor mol-
ecule by cleavage by b- and c-secretases [33].
Although many studies have demonstrated physiologi-
cally relevant regulation of ADAM10 activity by TIMPs
[34], little is known about the initial activation of
ADAM10 [32]. While the proprotein convertase furin
cleaves the propeptide proADAM10 at the maturation site
RKKR in the secretory pathway, the globular propeptide
remains noncovalently bound to the active site thereby still
inhibiting the protease [35]. Thus, how ADAM10 gains
catalytic competence in vivo by complete removal of the
propeptide is unknown, but this is an important question
in the understanding of Alzheimer’s disease where the
a-secretase activity is outweighed by pathological cleavage
by b- and c-secretases [18, 32].
In the present work, terminal amine isotopic labeling of
substrates (TAILS) [36, 37] was used to identify the
cleavage sites of native protein substrates of meprins a and
b by N-terminal peptide enrichment and proteomic analy-
ses. We identified physiologically relevant meprin
substrates in the cellular context, which is important for
identifying physiologically relevant targets [21, 24, 38, 39].
Of the 151 substrates identified with high confidence, one
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of the most interesting was cleavage in the propeptide of
ADAM10 by meprin b, potentially leading to propeptide
destabilization and release from the catalytic domain, so
completing activation. We also describe a broad range of
protease inhibitors that are cleaved by meprins including
LEKTI, implicating meprins in the indirect regulation of
KLK activity. Finally, we found several natural inhibitors
of meprins that we propose as important for in vivo regu-
lation of these two proteases.
Materials and methods
Protein expression and purification of meprin, APP
and proADAM10
Human meprin a and b were expressed and purified
according to previously published methods [2, 40].
APP695 and APP751 were produced as described in pre-
viously [16]. A truncated version of murine proADAM10
was engineered for recombinant expression lacking the
ADAM10 signal peptide and regions C-terminal of the






Constructs were ligated into pFastBac (Gibco) contain-
ing the meprin b signal peptide, followed by a 69 His-tag,
resulting in the expression of soluble proADAM10. Prim-
ers were synthesized by Invitrogen GmbH and sequences
of constructs were verified by DNA sequencing (GENter-
prise GmbH).
Recombinant protein was expressed using the Bac-to-
Bac expression system (Gibco) following the manufac-
turer’s instructions. All media and supplements were
obtained from Gibco. Recombinant baculoviruses were
amplified in adherently growing Spodoptera frugiperda
(Sf-9) insect cells at 27 C in Grace’s insect medium sup-
plemented with 10 % fetal bovine serum, 50 units/ml
penicillin and 50 lg/ml streptomycin. Protein was expres-
sed in 500 ml suspension cultures of BTI-TN-5B1-4
(HighFive) insect cells growing in Express Five SFM sup-
plemented with 4 mM glutamine, 50 units/ml penicillin and
50 lg/ml streptomycin in Fernbach flasks using a Multitron
orbital shaker (Infors AG). Cells were infected at a density
of 2 9 106 cells/ml and protein expression was stopped
after 72 h; media were stored at -20 C until further use.
Recombinant APP was further purified from the media
by ammonium sulfate precipitation (60 % saturation), stir-
ring overnight at 4 C, followed by centrifugation at
11,000 g for 2 h at 4 C. Pellets were dissolved in 1/10
volume of 50 mM NaH2PO4, 300 mM NaCl, pH 8.0, and
dialyzed against a solution containing 50 mM NaH2PO4,
300 mM NaCl and 10 mM imidazole, pH 8.0, and then the
protein solution was loaded on a Ni–NTA column. After a
washing step using a solution containing 50 mM NaH2PO4,
300 mM NaCl and 25 mM imidazole, pH 8.0, protein was
eluted with the same buffer containing 50 mM imidazole,
pH 8.0. ProADAM10 was analyzed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
western blot (monoclonal Penta His 1:1000; Qiagen), and
MALDI-TOF at the Institut Fe´de´ratif de Recherche (IFR)
128 (Lyon, France).
Cell culture
HaCaT, HEK293, Caco2 and U373 cells were grown each
in Dulbecco0s modified Eagle’s medium (DMEM) Gluta-
MAX (Invitrogen) supplemented with 5 % calf serum until
they reached approximately 60–80 % confluence. Caco2
and U373 cells were transiently transfected with full-length
meprin b-pIRES2-EGFP cDNAs with the Nanofectin
transfection reagent (PAA Laboratories GmbH) according
to the manufacturer0s instructions. Transfections were
carried out for 24 h, after which all cell cultures were
washed with serum-free and phenol-free DMEM (Invitro-
gen). Nontransfected cells were treated with 5 nM
recombinant meprin a or 5 nM recombinant meprin b.
Cells were incubated for 24–72 h, depending on viability,
in serum-free and phenol-free DMEM either as transfec-
tants, with recombinant enzyme or not treated. Samples of
transfected cell medium and lysate were used for detection
of meprin b by using a polyclonal anti-meprin b antibody
[2]. Signal detection in all western blotting experiments
was carried out by enhanced chemiluminescence (ECL).
For expression of proADAM10, HEK293 monolayers
(70–80 % confluence) were transiently transfected with
full-length proADAM10-pc DNA or pc DNA as mock
controls as described above. Culture supernatant was col-
lected 24 h after transfection.
Collection of cell media
After removal of secretome for TAILS analysis, the fol-
lowing protease inhibitors were added: 1 lM E-64 (L-trans-
epoxysuccinyl-leucylamido-(4-guanidino)butane), 1 mM
ethylenediaminetetraacetic acid (EDTA) and 0.5 mM
phenylmethanesulfonylfluoride (PMSF). To remove cells
and cell debris, the medium was centrifuged for 5 min at
500 g and the supernatant for 30 min at 8,000 g. Clarified
secretome was 109 concentrated using 3 K centrifugal
filter units (Millipore), simultaneously exchanging the
TAILS proteomics analysis of meprin a and b 311
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buffer with 10 mM HEPES, pH 7.5. The Bradford assay
was used to determine protein concentrations.
TAILS
Cells were grown in DMEM, 5 % calf serum to 70 % con-
fluence, washed extensively to remove serum proteins, and
grown overnight in serum-free medium. Cells were washed
again, incubated in phenol red-free, serum-free medium and
incubated with recombinant human meprin a or b. Condi-
tioned medium proteins were harvested at 48 h when the
cells were between 80 and 90 % confluence. Protease
inhibitors (1 mM EDTA, 1 mM PMSF) were immediately
added and the medium clarified by centrifugation (5 min,
500 g), filtration (0.22 lm) and additional centrifugation
(30 min, 8,000 g). The proteins were 1009 concentrated by
ultrafiltration using Amicon Ultra-15 centrifugal filter units
(3 kDa cut-off; Millipore). The sample buffer was changed
to 50 mM HEPES, 150 mM NaCl and 10 mM CaCl2 by five
cycles of dilution and concentration in the same concen-
trating device. Protein concentrations were determined using
the bicinchoninic acid (BCA) assay (Pierce) and the Brad-
ford assay (BioRad). The TAILS procedure including
isotopic labeling, tryptic digestion, amine-terminal blocked
peptide enrichment, liquid chromatography-MS/MS, data
analysis and peptide abundance ratio was performed as
previously described [36]. MS2 spectra were searched
against the human International Protein Index protein data-
base (v.3.42; 72,346 protein entries) using Mascot version
2.2 (Matrix Science) or X! Tandem (2007.07.01 release).
The following parameters were applied: semi-ArgC cleav-
age specificity with up to two missed cleavages, cysteine
carbamidomethylation and peptide lysine iTRAQ as fixed
modifications, and N-terminal iTRAQ, N-terminal acetyla-
tion and methionine oxidation as variable modifications.
Tolerance for precursor and fragment ions was set at 0.4 Da,
and the ESI-QUAD-TOF scoring scheme was used. Sec-
ondary validation was performed using the Trans Proteomic
Pipeline (TPP v. 4.2, rev. 0, build 200811181145) [41, 42]
using the PeptideProphet [43] and iProphet [44] algorithms
for peptide/protein assignment, and iTRAQ reporter ion
intensities were quantified using Libra. Peptides were fil-
tered by iProphet scoring, and only assignments with a
probability C0.95 were included in further analysis. Multi-
ple spectra were merged for individual peptides, and reporter
ion intensity ratios were calculated by intensity-dependent
weighted averaging using statistical models described pre-
viously [36, 45]. Accordingly, peptides with a protease/
control iTRAQ ratio of C10 were considered as only present
in the protease-treated sample and thus derived from the
activity of the test protease. Peptides with a ratio of less than
ten require biochemical validation to confirm that they rep-
resent cleavage sites in native protein substrates.
Primary murine fibroblast isolation
Tissue biopsies from the ears of 6-week-old meprin b-/-
and wild-type mice were excised, cut into small pieces
using a sterile scalpel, and washed in 70 % ethanol for
2 min. After incubation in 0.05 % trypsin for 48 h at 4 C,
pieces were transferred to 25-cm2 cell culture flasks coated
with fetal calf serum coated, and after 48 h of incubation
cultured in DMEM supplemented with 10 % (vol/vol) fetal
calf serum and 50 lg/ml gentamicin. Ear pieces were
incubated every 48 h with 0.05 % trypsin until the first
cells adhered. The medium was changed after 48 h and the
cells cultured until confluence.
Generation of meprin b-expressing cells
HEK293 cells were transfected with plasmid pIRES2-
EGFP-meprin-b-HA using lipofectamine 2000 (Invitrogen)
and selected via G418 to generate stable cell lines. Selected
cells stably expressed C-terminal HA-tagged human me-
prin b and EGFP.
Meprin b cleavage assays and inhibitor treatments
Cells were seeded into six-well plates coated with poly-L-
lysine. For stimulation, mouse embryonic fibroblasts (MEF)
and HEK cells were grown to 80–90 % confluence. Cells
were washed twice with serum-free DMEM and then
secretion medium (serum-free DMEM supplemented with
2 mM glutamine) was added. For induction of shedding,
either phorbol 12-myristate 13-acetate (PMA, 1 lM) or
A23187 (1 lM) was added for 3 h. MEF were then analyzed
by flow cytometry. Experiments in the presence of metal-
loprotease inhibitors (GM6001, 25 lM; GI254023X,
25 lM or 100 nM) were performed by preincubating HEK
cells with inhibitor in secretion medium for 1 h at 37 C and
then PMA or A23187 was added for 3 h. In control exper-
iments, the solvent DMSO was present in all incubation
steps. After the appropriate incubation time, cell culture
supernatants were collected, centrifuged for 10 min at
660 g and proteins precipitated with 10 % trichloroacetic
acid at 4 C. Proteins were analyzed by western blotting. For
comparative and quantitative analysis, solvent-treated cells
were used as controls with the effects observed set to 100 %.
SDS-PAGE and western blot analysis
SDS-PAGE was performed according to standard proce-
dures in 10, 12 or 16 polyacrylamide gels. Coomassie
brilliant blue was used for background-free gel staining
[46]. For immunoblot analysis proteins were subjected to
electrophoresis under reducing conditions and then trans-
ferred onto a PVDF membrane (Immobilon P; Millipore)
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by western blotting. For detection with polyclonal anti-
bodies, the membrane was saturated with 5 % dried milk in
Tris-buffered saline for 1 h, incubated with the first anti-
body for 1 h and subsequently with horseradish peroxidase-
conjugated antirabbit IgG (1:10 000) for 1 h at room
temperature. Proteins were detected using Rotilumin (Roth)
following the manufacturer’s instructions using X-ray film
(Hyperfilm ECL; Amersham Pharmacia Biotech). For
detection with monoclonal antibodies (1:1,000), the mem-
brane was blocked with 3 % bovine serum albumin and
incubated with the appropriate antibody. The secondary
antibody (antimouse, coupled with horseradish peroxidase,
1:10,000) was added for 1 h, and ECL (Millipore) was used
for subsequent detection. For detection of total murine
ADAM10 protein in fibroblasts, a polyclonal ADAM10
antibody directed to the C-terminus was applied [47].
Processing of recombinant proteins by meprin a and b
The substrates were incubated with 50–100 nM recombi-
nant meprin a or b at 37 C in 50 mM HEPES, pH 7.5.
ProMMP1, LEKTI and KLK7 were expressed and purified
as described previously [48–50]. Other proteins were pur-
chased as follows: IGFBP-3 (Immunotools), VEGF-A165
(Cell Signaling), syndecan-4 (R&D Systems), cystatin C
(BioVendor), elafin (ENZO Life Sciences), fetuin-A
(Sigma), secretory leukocyte protease inhibitor (SLPI;
R&D Systems), stratifin (Sigma) and desmoglein-1 (R&D
Systems). Assay reaction products were subjected to SDS-
PAGE and either stained with coomassie blue or analyzed
by western blotting. The following antibodies were used:
anti-FGF-19 (Bio Vision; 1:1,000, polyclonal), anti-IG-
FBP-3 (Immunotools; 1:1,000, polyclonal), anti-VEGF-A
(Santa Cruz Biotechnology; 1:200, monoclonal), anti-N-
APP (Thermo Scientific; 1:200, polyclonal), anti-His-tag
(Qiagen; 1:1,000, monoclonal), anti-LEKTI (H-300; Santa
Cruz Biotech; 1:200, polyclonal), anti-MMP1 (Abcam;
1:1,000, polyclonal), anti-stratifin (Firma; 1:1,000, mono-
clonal), and anti-ADAM10 (Abcam; 1:1,000, polyclonal).
Identification of cleavage sites
For N-terminal sequencing, proteins were separated by
SDS-PAGE, blotted onto PVDF membranes for Edman
degradation, stained with coomassie brilliant blue, and then
analyzed at the Protein Micro-sequencing Centre of the
Institut Fe´de´ratif de Recherche (IFR) 128 (Lyon, France).
Inhibition studies
Inhibition of meprin by elafin was compared with activity
after incubation with fetuin-A and cystatin C used as
positive controls [51]. The inhibition assay of meprin a and
b was performed using 5 9 10-5 M elafin. The inhibitory
potential of SLPI (1 lM) and LEKTI (100 nM) after
meprin cleavage (100 nM and 10 nM, respectively) was
demonstrated by the analysis of (chymo)tryptic substrates.
Following incubation of inhibitors with meprin a or b for
30 min at 37 C, meprin activity was blocked by the
addition of 200 nM of the specific inhibitor actinonin for
15 min at 37 C. The inhibitory capacity of SLPI against
KLK7 was determined using the quenched fluorogenic
substrate Suc-LLVY-AMC (Bachem) at a final concentra-
tion of 100 lM. KLK2 activity was detected using Z-Pyr-
G-R-AMC (Peptanova) at a final concentration of 100 lM.
The enzyme activity was measured with a SynergyTM HT
reader (BioTek). The proteolytic activity was determined
in relation to the emission at 405 nm with excitation at
320 nm. The activity was determined from the slope of the
initial linear range of the curve.
Activity assays using fluorogenic peptides to validate
catalytic properties of proADAM10 and meprin b
To test the enzymatic efficiency of proADAM10 and
ADAM10 activated by meprin b and meprin b alone,
quenched fluorogenic peptide substrates were used: Mca-
KPLGLA2pr(Dnp)AR-NH2 for proADAM10 (Peptanova)
and Mca-YVADAPK(Dnp)-NH2 for meprin b (Peptide
Institute Inc.) which was used at a final concentration of
10 lM. The enzyme activity was measured with a Varioskan
Flash fluorescence spectrometer (Thermo Scientific). Data
were analyzed using SkanIt Software 2.4 for Varioskan
Flash. Enzymes were buffered in 50 mM HEPES, pH 7.5,
and proADAM10 was used at a final concentration of 10 lM
and meprin b at 15 nM. The ADAM10 inhibitors GI2540
23X and GM6001 were added each at a final concentration of
10 lM and preincubated for 20 min at room temperature.
ADAM activity in cell culture supernatants from murine
fibroblasts was measured at 37 C, and the fluorescence was
detected every 12 s for 120–240 min. Proteolytic activity
was determined in relation to the emission at 405 nm with
excitation at 320 nm. The activity was determined from the
slope of the initial linear range of the curve.
Quantitative real-time PCR
Total RNA was isolated from primary fibroblasts of wild-
type and meprin b knockout mice (n = 3) according to the
instructions with the GeneJET RNA purification kit
(Fermentas, Thermo Scientific) and transcribed into com-
plementary DNA using RevertAidTM transcriptase (200
U/ml), 10 mM nonspecific oligo d(T) primers, and 200 mM
dNTPs (Fermentas, Thermo Scientific). The cDNA obtained
was subjected to quantitative real-time PCR using a Light-
Cycler480 real-time PCR system (Roche Applied Science).
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Amplification reaction consisted of a hold of 10 min at 95 C
and 45 cycles (10 s/95 C, 30 s/60 C). For assay design the
Universal ProbeLybrary system (http://qpcr.probefinder.
com/roche3.html) was used to amplify intron spanning
regions for the gene of interest. Relative amounts of target
gene mRNA were normalized to the housekeeping gene
GAPDH. The following primers/probes were used:
ADAM10 sense: 50-gggaagaaatgcaagctgaa-30
ADAM10 antisense: 50-ctgtacagcagggtccttgac-30
DDCp values were used to calculate the relative
expression for each data point.
Flow cytometry
Tumor necrosis factor-a converting enzyme (TACE)
knockout MEF cells (5 9 105), untreated or stimulated
with PMA or A2318, or DMSO as control, were detached
from the cell culture plate with Accutase (PAA Laborato-
ries GmbH) and washed twice with FACS buffer (1 %
BSA in PBS). Following centrifugation at 1,000 g for
5 min at 4 C, cells were blocked with 10 % FCS in PBS
for 15 min. After pelleting, cells were incubated with a
polyclonal meprin b antibody (1:1,000) in FACS buffer for
60 min on ice. Cells were then washed once in FACS
buffer and incubated with Alexa Fluor 647-conjugated goat
antirabbit antibody for 30 min on ice. After a final wash,
cells were resuspended in FACS buffer and analyzed by
flow cytometry (FACS Canto; Becton–Dickinson, Heidel-
berg, Germany). All assays were carried out in triplicate.
Data were analyzed using FCS Express v. 3 (De Novo
Software, Los Angeles, CA).
Animal and tissue preparation
Muscle, kidney, intestine and hippocampus from wild-type
and meprin knockout animals were isolated as previously
described in [16].
Supplementary data
Supplementary data are available online from Cellular and
Molecular Life Sciences journal at www.springer.com.
Results
Proteomics analysis of proteins cleaved
by meprin a and b in the cellular context
To identify extracellular substrates of meprin a and b, we
analyzed the secretome of HaCaT, HEK293, Caco2 and
U373 cells incubated with recombinant meprin a and b.
We also analyzed secretomes of HaCaT, Caco2 and U373
cells that had been transfected to express full-length
membrane-bound meprin b. As a control, HEK293 cells
Fig. 1 TAILS workflow for proteomic meprin a and b substrate
screening. The serum-free proteomes of cells of the human cell lines
HEK293 (human embryonic kidney), HaCaT (human adult low-
calcium high-temperature), U373 (glioblastoma) and Caco2 (colon
cancer) treated with recombinant soluble meprin a or b or transiently
transfected with full-length meprin b were collected and compared to
those of control cells. N-termini of the whole isolated proteins were
labeled with iTRAQ reagents. Following tryptic digestion internal
peptides were blocked and removed by polyaldehyde dendritic
polymer and N-termini (natural or iTRAQ-labeled) were enriched
for liquid chromatography on a HPLC system. Labeled peptides were
analyzed by MS/MS with m/z peaks of 114 and 115. Cleavage sites
were often validated by Edman sequencing. iTRAQ quantification
allowed up to eight samples to be analyzed simultaneously using eight
isobaric tags. HPG hyperbranched polyglycerols, ALD HPG aldehydes
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were treated twice with recombinant meprin b to validate
reproducibility (Fig. 1, Online resource 1). By MS/MS
(tandem mass spectrometry) using an ion cut-off ratio of
3.0, we identified with high confidence 151 new extracel-
lular N-terminal peptides, of which 117 had a ratio of
C10.0, as extracellular substrates of meprin a and b.
The most promising candidates were classified into six
categories.
Other proteases
Interestingly, a large number of substrates identified by
TAILS were proteases (Fig. 2). ADAM9 and ADAM10,
commonly known as a-secretase candidates in nonpatho-
logical APP processing [52], were both specifically cleaved
by meprin a and b. Special regard was paid to ADAM10
where meprin b-transfection of Caco2 cells (Table 1) led to
cleavage between Gly109 and Glu110 within the 194 amino
acid propeptide (Fig. 3a). To validate this, recombinant
proADAM10, N-terminally tagged with six histidines and
lacking the C-terminal region downstream of the protease
domain to ensure solubility, was produced by heterologous
expression in baculovirus-infected insect cells and subse-
quently purified by Ni-NTA chromatography (Fig. 3b).
Western blot analysis of the purified proADAM10 domain
and MALDI-TOF analysis verified the identity of the pro-
tein revealing the full-length ADAM10 dimer, the catalytic
domain (40 kDa) and the prodomain (30 kDa) (Fig. 3b, c).
Recombinant proADAM10 was processed by meprin b and
yielded in a decrease in the mass of the 100-kDa proAD-
AM10 dimer and the 30-kDa propeptide resulting in minor
molecular weight fragments indicating a meprin b-medi-
ated cleavage event (Fig. 3c). As analyzed using the
fluorescence resonance energy transfer (FRET) peptide
Mca-KPLGLA2pr(Dnp)AR-NH2, we found a significantly
increased activity of ADAM10 after meprin b cleavage
(Fig. 3d). The activity of proADAM10 and meprin b-acti-
vated ADAM10 was in both cases fully inhibited using the
hydroxamate inhibitors GI254023X and GM6001 at con-
centrations of 10 lM specific for ADAM inhibition [53]. In
assessing the biological relevance of this cleavage, the
activity of ADAM10 was reduced from 100 % to 51 % in
primary murine meprin b-/- fibroblasts compared to
meprin b-expressing control cells (Fig. 3g). Interestingly,
while the expression of ADAM10 measured by quantitative
real-time PCR in wild-type cells was significantly lower
than in meprin b-/- fibroblasts (Fig. 3e), the total protein
level of ADAM10 was not dramatically different, although
a b
c d e
Fig. 2 Classification of meprin substrates identified by TAILS. To
date, the majority of known substrates for meprins is from analysis of
isolated proteins in vitro (a). By proteomic screening of cells of the
human cell lines HEK293 (b), U373 (c), HaCaT (d) and Caco2
(e) novel substrates were identified including inhibitors, receptors,
proteases and other proteins with uncharacterized functions. Catego-
ries were determined based on UniProt database entries. Numbers of
identified substrates are given in parentheses. IL immunological, GF
growth factor, ECM extracellular matrix
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the mature form of ADAM10 was slightly lower in meprin
beta-/- cells (Fig. 3f).
It has previously been demonstrated that ADAM17
(TACE) is a sheddase for human meprin b [3]. We deter-
mine whether ADAM10 is not only activated by meprin b
but might also shed meprin b from the cell surface. In
HEK293 cells transiently transfected with ADAM10
(Fig. 3h) we demonstrated an increase in meprin b activity
in the supernatant of 40 % (Fig. 3i). To confirm that
ADAM10 was a constitutive sheddase of membrane-bound
meprin b in a cellular system (Fig. 4), we induced
endogenous ADAM10 expression by PMA (Fig. 4a) and
the calcium ionophore A23187 (Fig. 4b). This resulted in a
significant threefold enhancement of soluble meprin b in
the supernatant as determined by western blotting using a
polyclonal antibody specific for meprin b (Fig. 4a, b).
Correspondingly, PMA induction resulted in reduced levels
of membrane-bound meprin b expression in cells with or
Table 1 Protease substrates for meprin a and b identified by TAILS
Proteins were analyzed from cell culture media as indicated in the third column after 24 and 48 h, respectively. Caco2 cells were additionally
transfected with full-length meprin b cDNA before the conditioned culture medium was collected. Identified substrates presented here are
members of the metalloprotease family or belong to the serine proteases. Proteins in italic have been further validated in vitro (Fig. 3). Sequences
are given in the one letter code. Arrows indicate the cleavage sites analyzed by MS/MS for meprin a (a) and meprin b (b). Asterisks indicate
substrate cleavage sites validated by Edman sequencing. Numbers indicate the position of amino acids in full-length protein. Confirmed cleavage
sites in more than one secretome are indicated in bold.
MMP matrix metalloprotease, ADAM disintegrin and metalloprotease domain-containing protein 9, ADAMTS-1 disintegrin and metalloprotease
with thrombospondin motifs, BMP bone morphogenetic protein, PCSK proprotein convertase subtilisin/kexin type 9, KLK kallikrein, TNF tumor
necrosis factor.
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without ADAM17 activity (Fig. 4g, h). Probably due to
low expression of endogenous meprin b in these cells, the
calcium ionophore ionomycin (A23187) did not signifi-
cantly induce ectodomain shedding. Meprin b shedding
was potently blocked by the inhibitors GI254023X and
GM6001 at nanomolar concentrations in cells in both the
presence and absence of PMA and A23187 (Fig. 4c–f).
Expression of membrane-bound meprin b was not affected
by PMA or A23187 stimulation as detected in the cell
lysates. Thus, meprin b finalizes the activation of
ADAM10 by a destabilizing cleavage in the propeptide of
ADAM10 that releases the furin-cleaved propeptide from
the catalytic domain. In turn, activated ADAM10 contrib-
utes to the shedding of meprin b from the cell surface,
possibly forming a feedback loop to control cell-surface
activity levels of these two metalloproteases.
Inhibitors
Eight protease inhibitors were identified by TAILS as
meprin substrates through identification of meprin cleavage
sites (Table 2). These included cystatin C and fetuin-A,
which we have previously shown to be endogenous
inhibitors of meprin a, with fetuin-A also an inhibitor of
meprin b [51] (Online resource 2).
Five cleavage events within the inhibitor elafin were
determined by TAILS analysis, all five of which were within
the trappin protein transglutaminase binding domain
(TPTBD) at position Gln56/Asp57 by both meprins, which is
not present in the recombinant protein we used to validate
these proteomic findings, and at Lys60/Ala61 by meprin a,
and at Ala61/Gln62, Gln62/Glu63 and Ser70/Thr71 by
meprin a and b. Cleavage at Lys66/67Gly was due to
meprin a cleavage only (Fig. 5a). Ser70/Thr71 is a cleavage
site N-terminal of the whey acidic protein-type (WAP-type)
domain, suggesting that this might modulate its antimicro-
bial activities [54]. Edman degradation was used to validate
this cleavage in vitro and the N-terminal sequence exactly
matched that obtained in the TAILS data. Thus, even though
other proteases and inhibitor activity levels were modified
by meprin activity, it is highly likely that in the cell culture
experiments the TAILS data reflected direct action of
meprin. Analysis of the inhibitory potential of elafin revealed
inhibition of meprin a but not of meprin b (Fig. 5a).
TAILS also revealed that SLPI is processed by meprin a
and b within its second WAP domain. We validated
meprin a cleavage of SLPI in an in vitro assay, by SDS-
PAGE and by FRET analysis (Fig. 5b). Notably, cleavage
by meprins occurred at the reactive bond of this inhibitor
with Leu97and Met98 being critical for inhibition of chy-
motrypsin and elastase. Interestingly, SLPI is also cleaved
by MMP14 determined previously by ICAT proteomics in
the cellular context [55], that showed inactivation of SLPI.
Surprisingly, cleavage of SLPI by meprin a significantly
increased the inhibitory capacity of this molecule towards
the serine protease KLK7 (Fig. 5b).
Another serine protease inhibitor, LEKTI, was shown by
TAILS to be cleaved by both meprin a and b (Fig. 5c, d).
LEKTI consists of 15 potential inhibitory domains, of
which two resemble Kazal-type inhibitors and the other 13
are structurally related but lack one of the three typical
disulfide bridges [56, 57]. Western blot analysis showed
processing of full-length LEKTI mediated by both
meprin a and meprin b that resulted in a shift from 130 to
80 kDa on SDS-PAGE gels (Fig. 5c). According to the
TAILS data, cleavage of the last domain of the recombi-
nant LEKTI construct (9–15) by meprin b specifically led
to a loss of about 10 kDa in mass (Fig. 5d). The activity of
KLK2 after incubation with LEKTI 9–15 mediated by
meprin b was about 20 % higher than after LEKTI 9–15
pretreatment due to the presence of the additional domain.
We identified two further cleavage sites in LEKTI with ion
cut-off ratios of \3.0 between Arg489/Glu490 and Arg625/
Glu626 in domains 9 and 10, respectively. Processing by
either meprin a or b between domains 7 and 8 with addi-
tional cleavage of domain 15 resulted in a cleaved protein
with a predicted size of 80 kDa.
Growth factors
We identified fibroblast growth factor 19 and the growth
factor associated insulin growth factor binding protein 3
(IGFBP-3) as substrates for both meprin a and b (Table 3).
Western blotting confirmed that IGFBP-3 (38 kDa) was
cleaved by both meprin a and b (Fig. 6a, b) to two frag-
ments of 22 and 18 kDa, in agreement with size predictions
from the TAILS analysis (Fig. 6a, b).
Extracellular matrix proteins
Both meprin a and meprin b can be released from the cell
membrane to the extracellular space [8] where they can
cleave collagen IV [58] and procollagen III [15]. We
identified two additional substrates from the collagen fam-
ily for both meprins (Table 4). Collagen a-2 (I) is cleaved
by meprin a and/or b N-terminally at Ser356, Gly367, Gly556,
Glu596, Thr981, Gly1054, Asp1109 and Asn1144. Neo-N ter-
minal peptides of collagen a-1 (XVIII) commence at
Glu444, Glu679 and Asp732 representing the P10 residues in
the cleavage site. TTGF-b-induced protein ig-h3 (TGFBI),
an adhesion molecule that binds to type I fibrillar collagen
[59] and is associated with bone formation, was also iden-
tified by TAILS as a meprin substrate (Table 5).
The collagen-binding HSP47 (Table 5), a member of the
serpin family and serving as a chaperone [60], was detected
as a novel substrate for meprin a and b cleaving between
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Arg103/Asp104 and Asn174/Glu175. Several known sub-
strates of meprin a and b, namely the collagen-binding
proteins nidogen-1, nidogen-2, laminin-5c and fibronectin
(Table 4) [58, 61, 62], were identified in the TAILS anal-
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Several proteoglycans were identified as substrates by
TAILS, e.g. syndecan-1 and -4 (Table 4) (Fig. 6). Pro-
cessing of the 28-kDa syndecan-4 was confirmed when two
fragments derived from meprin b with molecular masses of
18 and 16 kDa were detected using a monoclonal antibody
specific for the C-terminal His-tag of recombinant synd-
ecan-4 (Fig. 6c, d). The sizes of these cleavage fragments
are consistent with cleavage at Glu70/Asp71 as identified by
the neo-N-terminal peptide identified by TAILS (Fig. 6c,
d). In contrast, meprin a led to degradation yielding several
proteolytic fragments (Fig. 6d). Although meprin b
cleaved both proteins in vitro (Fig. 6c, d), only syndecan-4
was identified as a substrate for meprin b by TAILS. This
may be because the protein was fully degraded in culture or
because the cleavage site lies too close to or too far from an
arginine so that the neo-N-terminal peptide is either too
short or too long, respectively, for MS identification.
Alternately, in a cellular context or in the presence of other
molecules, not every potential cleavage site is accessible to
the protease.
Finally, the neuronally relevant cadherin-2 and tenas-
cin C were also identified as substrates by TAILS. Tenascin
C has recently been found to be cleaved by meprin b and
possibly to be involved in Crohn’s disease [63].
Other substrates
Stratifin, a keratinocyte-specific 14-3-3 protein, was dem-
onstrated to be a substrate for meprin b in TAILS, and this
was confirmed in vitro (Fig. 6e–g). Processing by meprin b
was much more efficient than that by meprin a, but both
yielded a 23-kDa fragment (Fig. 6f). By N-terminal
sequencing, the identified meprin b cleavage site between
Cys96 and Asp97 corresponded exactly with that identified
by TAILS (Fig. 6g). Table 5 lists additional substrates for
meprin a and b that were identified by neo-N-terminal
peptides with high iTRAQ ratios.
In total, 151 substrates were identified with high confi-
dence by TAILS, and notably those with cleavage
fragments sequenced by Edman degradation in in vitro
validation experiments exactly matched the TAILS data.
The many examples of this presented here confirms the
fidelity of TAILS as a reliable terminomics approach for
identifying substrates of proteases, particularly those hav-
ing a loose cleavage site consensus sequence that makes
manual parsing of data unreliable for substrate finding.
Discussion
Limited proteolytic processing is a crucial molecular
mechanism affecting regulation of almost every protein
function [22, 23, 64]. Proteases and their endogenous
inhibitors build complex dynamic proteolytic systems that
are highly interconnected with the signaling networks of
chemokines, cytokines and growth factors. To understand
this regulatory impact of proteases, whose action is exe-
cuted by proteolytic activation, it is necessary to
systematically elucidate their substrates and the specific
cleavage sites within the proteins [4]. Using TAILS, we
identified with high confidence 151 extracellular meprin a
and b substrates demonstrating an unexpectedly large and
diverse substrate degradome for these two proteases. With
33 substrates only reported for human meprins in MER-
OPS, the protease database [65], and our confirmation of
10 of these known substrates, the identification of a large
number of novel substrates by TAILS (141), many of
which we validated biochemically, provides a considerable
new insight into the in vivo functions of both meprin a and
meprin b that until recently have been somewhat
enigmatic.
Loss of one protease can raise or decrease the activity of
others either directly through altering the activation cas-
cade, shown here for ADAM10, or indirectly by cleaving
and removing the activity of a protease inhibitor from the
system and hence increasing activity of its cognate prote-
ase, as we showed for the inhibitors LEKTI, SLPI, elafin
and cystatin C, for example. Previous data have shown that
Fig. 3 Activation of proADAM10 by meprin b. a Schematic struc-
ture of ADAM10 indicating the cleavage site identified by TAILS for
meprin b. Cleavage occurs within the propeptide of ADAM10
between Gly109 and Glu110. CRD cysteine-rich domain, EGF
epidermal growth factor-like domain, TM transmembrane domain,
C cytoplasmic tail. b Recombinant proADAM10 was expressed in
insect cells and purification was facilitated using an N-terminal His-
tag. Purified proADAM10 was subjected to SDS-PAGE and analyzed
by western blotting with an anti-His-tag antibody, detecting the
prodomain of ADAM10 (triangle). c Recombinant proADAM10 was
proteolytically processed by meprin b at 37 C for 1 and 5 min
(asterisk proADAM10 dimer). After incubation with meprin the
propeptides are cleaved (cat_ADAM10; arrowhead, triangle prodo-
main). d The relative activity of ADAM10 was monitored using the
FRET peptide Mca-KPLGLA2pr(Dnp)-AR-NH2. The ADAM10
concentration was 10 lM and 15 nM for meprin b, inhibitors
GI254023X and GM6001 were used at a final concentration of
1 lM. e, f Quantitative real-time PCR (qRT-PCR) and western
blotting were used to detect ADAM10 expression in wild-type (wt)
and meprin b knockout (b-/-) fibroblasts. g Primary murine
fibroblasts of meprin b-/- mice show a reduced ADAM10 activity
compared to their wild-type counterparts measured using the
ADAM10 fluorogenic substrate (wt wild-type). h HEK293 cells were
transiently transfected with full-length ADAM10 cDNA and activity
was determined by the ADAM10 FRET substrate. Untransfected
wild-type and mock-transfected cells were used as controls. i
Meprin b activity is increased fivefold in ADAM10-overexpressing
HEK293 cells determined by the meprin b-specific FRET peptide
Mca-YVADAPK(Dnp)-NH2. Untransfected wild-type and mock-
transfected cells were used as controls. For quantification all
experiments were performed in quadruplicate. Significance was
determined by the t test (**p \ 0.05; ***p \ 0.01)
b
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meprins are involved in the progression of several patho-
logical conditions, but the substrates in these diseases are
largely unknown [8]. Our findings reveal proteolytic
molecular interactions that link to possibly explaining
some of these events. We demonstrated that meprin b is an
activator of ADAM10, a metalloprotease known to be
important for development and tissue maintenance, medi-
ated by Notch or EGFR ligand shedding [20]. The lack of
meprin in knockout mice is correlated with aggravated
chronic inflammation, but specific substrates have been
elusive [66]. The reduced ADAM10 activity found in
meprin b knockout mice would clearly have impact on
inflammatory processes such as inflammatory bowel dis-
ease, since it has been shown that ADAM10 cleaves
inflammatory cytokines [67]. However, such an association
between a protease and its activator also renders it difficult
to ascribe the murine phenotype to either protease without
further experimentation [68].
ADAM10 is synthesized as a zymogen requiring pro-
teolytic activation. Although proprotein convertase PC7
and furin are known to process the propeptide at the mat-
uration site RKKR, a second cleavage event is necessary to
release mature ADAM10 from the prodomain [35]. How-
ever, the responsible proteolytic mechanism has been
elusive. Our data show that the meprins can activate
ADAM10 to completion not only in in vitro experiments,
but also in the cellular context. The propeptide is required
for proper protein folding and secretion of the cata-
lytic domain [69], but is also bound in a noncovalently
enzyme–propeptide complex, thereby inhibiting ADAM10
activity [35]. Isolated murine ADAM10 propeptide, for
example, selectively inhibits the catalytic domain of human
ADAM10 in the nanomolar range, both in vitro and in
cellulo, and in micromolar concentrations blocks the
activity of other ADAM family members [35].
The activation of ADAM10 by meprin b is of special
interest in relation to the development of Alzheimer0s
disease. Our findings suggest that increased a-secretase
activity mediated by meprin b potentially prevents pro-
gression of Alzheimer’s disease. We are presently initiating
further investigations with the aim of proving this possi-
bility, but in support of this hypothesis, we found altered
proteolytic processing of the APP in meprin b-expressing
mice compared to the animals lacking this protease (Online
resource 3).
ADAMs are also important for the shedding of proteo-
lytic enzymes from the plasma membrane [20, 70, 71].
ADAM10 itself is released from the cell surface through
cleavage by ADAM9 and ADAM15, indicating that
ADAM10 has dual functions in the cell [72].
The membrane-associated meprin b is shed from the
cell surface by ADAM17 (TACE) cleaving N-terminal to
the epidermal growth factor-like domain upon PMA stim-
ulation [3]. In our work, we showed ADAM10-mediated
meprin b shedding in cellulo, although ADAM17 was
found to be the major releasing enzyme. In contrast to the
membrane-tethered form, release of meprin b modifies
access to different substrates depending on cellular or
extracellular location. This is pertinent to meprin substrates
located at the cell surface, as known for APP [16]. The
release of cell surface proteases such as ADAMs and
meprin b by ectodomain shedding opens a fourth dimen-
sion (time) in proteolytic signaling that has to be taken in
account in further studies.
Consistent with the new network connections we found
between meprins and ADAMs, we found several cleavage
events that do not fit with the strong preference for nega-
tively charged amino acids in P10 [14]. The activity of
ADAM10 and KLK7 increases after meprin cleavage, and
so these proteases may contribute to the cleavage we
identified in the secretomes. Cleavage specificities for
KLK7 by positional scanning of the positions P1–P4
revealed that the chymotryptic protease favors tyrosine in
P1 and hydrophobic amino acids in P2 [73]. Hence, the
availability of the specificity profiles of other proteases
allows determination of whether an identified TAILS
substrate is a real meprin substrate or appears as a down-
stream effect. For example, ADAM19 (Tyr92/Thr93) and
the serum amyloid A protein (Tyr47/Ile48) show a typical
chymotryptic cleavage site with tyrosine in P1 indicating
that processing most likely takes place as a secondary event
and is not based on direct meprin cleavage.
Fig. 4 Effects of ADAM10 on ectodomain shedding of meprin b.
a, b Stable meprin b-overexpressing HEK 293 cells were incubated
for 3 h with PMA (1 lM, a), A23187 (1 lM, b) or DMSO as control.
The cell culture supernatants were then collected and the proteins
precipitated. Soluble meprin b was detected by western blotting using
a polyclonal antimeprin b antibody, followed by an antirabbit
antibody labeled with horseradish peroxidase and ECL. For quanti-
fication, the experiments were performed in quadruplicate. The
mean ? SD effects are indicated; significance was determined by
Student’s unpaired t test (*P \ 0.05, **P \ 0.01). c, d Meprin b-
expressing HEK 293 cells were preincubated for 1 h with GM6001
(25 lM) or DMSO as control, then PMA (1 lM, c) or A23187 (1 lM,
d) was added for 3 h. Soluble meprin b was detected by western blot
analyses as described above. For quantification the experiments were
done in triplicate. The mean ? SD effects are indicated; significance
was determined by the one-way ANOVA Bonferroni test (*P \ 0.05,
***P \ 0.001). e, f Meprin b-expressing HEK293 cells were prein-
cubated for 1 h with GI254023X (25 lM, e. or 100 nM, f) or DMSO
as control, then PMA (1 lM) was added for 3 h. Soluble meprin b
was detected by western blotting. For quantification the experiments
were done in triplicate. The mean ? SD effects are indicated;
significance was determined by the one-way ANOVA Bonferroni test
(*P \ 0.05, ***P \ 0.001). Secretion of meprin b in all tests is
indicated relative to the DMSO control. g, h Membrane-bound meprin
b levels were analyzed by flow cytometry in wild-type and TACE
(ADAM17) knockout cells incubated with DMSO (1 lM) as control,
PMA (1 lM) or ionomycin (A23187, 1 lM). A shift to the left
indicates reduced meprin b levels at the cell surface
b
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Cleavage of desmoglein-2 at Arg548/Gln549 also does not
match the canonical pattern for meprins, and desmoglein-2
is a known substrate of KLK7 and other KLKs under
(patho)physiological conditions [74]. Hence, both the
identified cleavage sites are probably due to effects
downstream from meprin activity. Serine protease 23
(Pro23/Tyr24) and the beta-2-microglobulin (Cys45/Tyr45)
also exhibited cleavage sites not typical of meprins.
ADAM10 has been shown to promote high selectivity for
Tyr in P10 [75] making the two substrates more likely due
to ADAM10 activity as a downstream effect.
Regulation of protease activity is also mediated by
endogenous inhibitors such as the four TIMPs for MMPs
and TIMP3 for ADAMs, which is crucial for the
orchestration of proteolytic signaling [23]. Recently, we
demonstrated that fetuin-A is an inhibitor of several as-
tacins including meprin a and b with an inhibition constant
(Ki) of 4.2 9 10
-5 M and 1.1 9 10-6 M, respectively
[51]. Here, we identified fetuin-A and cystatin C as sub-
strates for both meprins by TAILS (Online resource 2).
Concerning fetuin-A, the cleavage pattern after incubation
with meprin a was different than that with meprin b. With
regard to the inhibitory potential of fetuin-A and cystatin
C, kinetic studies indicated that cystatin C is a relevant
meprin a inhibitor, whereas fetuin-A exhibits stronger
inhibition of meprin b. We also evaluated the potential of
elafin as an inhibitor of meprin a which has an inhibition
mechanism similar to that of cystatin C. Meprin a was
Table 2 Inhibitor substrates for meprin a and b identified by TAILS
Cystatin C and fetuin-A identified in the conditioned media are known substrates; the others presented are new. Cleavage of cystatin C by
meprin a at position Asp41;Ala42 was identified in HaCaT and U373 cells. Serpin A3 was hydrolyzed in HaCaT and U373 cells at identical sites.
For clusterin, cleavage at position His263;Ser264 by meprin b was confirmed in U373 and HaCaT cells. Sequences are given in the one letter
code. Arrows indicate the cleavage sites analyzed by MS/MS for meprin a (a) and meprin b (b), asterisks indicate substrates validated by Edman
sequencing. Proteins in italic have been further validated in vitro (Online resource 2). Numbers indicate the position of amino acids in full-length
protein. Confirmed cleavage sites in more than one secretome are indicated in bold.
LEKTI lymphoepithelial Kazal-type-related inhibitor, Serpin serine protease inhibitor.





Fig. 5 Inhibitors identified by TAILS as substrates for meprin a and b.
a Elafin processed by meprin a was subjected to SDS-PAGE,
transferred to a PVDF membrane and visualized by coomassie blue
(CB) staining. The cleavage site identified by TAILS is indicated by the
asterisk. The presence of elafin (5 9 10-5 M) leads to a significant
reduction in meprin a activity measured by Mca-YVADAPK(Dnp)-
NH2 cleavage. Significance was determined by the t test
(***P \ 0.001). b Cleavage of SLPI by meprin a was demonstrated
by western blot (WB) analysis revealing a 12-kDa band. Incubation of
KLK7 with meprin a-processed SLPI (SLPI proc.) resulted in increased
inhibition compared to incubation with untreated SLPI. c, d Processed
fragments of full-length LEKTI 1–15 and LEKTI 9–15 were detected
by western blotting (WB) using a polyclonal LEKTI antibody. The full-
length protein was cleaved by meprin a and b, both releasing an 80-kDa
fragment. Specific processing of LEKTI 9–15 by meprin b resulted in a
shift from 60 to 50 kDa, matching the TAILS data. Incubation of KLK2
with LEKTI 9–15 resulted in lower proteolytic activity than incubation
with meprin b-cleaved LEKTI 9–14
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Table 3 Growth factor candidate substrates for meprin a and b identified by TAILS
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significantly inhibited by elafin while meprin b exhibited
increased activity. The possibility that the inhibitory
capacity was simply due to concurrent substrate effects was
excluded in our previous study in which we evaluated
meprin activity in the presence of a large excess of the
known substrate gelatin, and found no significant differ-
ence [51]. It seems likely that meprin inhibition by these
molecules is initiated by proteolytic cleavage. However,
only crystallization of an enzyme/inhibitor complex could
reveal appropriate information.
Cleavage of cystatin C by MMPs leads to inactivation
and a subsequent increase in cathepsin L activity [26].
Cystatin C was not simply degraded, but also inhibited
meprin a, whereas cleavage by meprin b rather resembled
the more selective MMP processing. Some protein inhibi-
tors appear to need an initial processing event to gain
inhibitory maturity, while others slip into inactivity
[76, 77]. In cystatin C, two cleavage sites for meprin a at
Arg34/Leu35 and Leu36/Val36 were detected by TAILS.
These have been previously found in urine from nephrol-
ogy patients [78]. The cleavage occurs one residue
C-terminal of the known reactive site for cystatin C, and
therefore may be decisive for meprin inhibition. Hence,
meprin expression and activity probably correlate with the
emergence of pathological disorders such as nephritis in
which meprin is upregulated [79, 80].
Interestingly, both meprin a and meprin b were able to
cleave the plasminogen activator inhibitor-2 (PAI-2 or
serpin B2) (Table 4). In the skin, PAI-2 has been shown
to be a substrate of transglutaminase-1 and to be cross-
linked into the cornified envelope [81]. Given that meprin
b is expressed in the stratum granulosum of the epidermis
[40], it is likely that under physiological conditions only
meprin b cleaves PAI-2. However, in Netherton
Table 3 continued
Vascular endothelial growth factor A (VEGF-A) and interleukin 18 (IL-18) are known substrates detected by TAILS as substrates within the class
of growth factors; the others are novel substrate candidates. Proteins in italic have been further validated in vitro (Fig. 6). Sequences are given in
the one letter codes. Arrows indicate the cleavage sites analyzed by MS/MS for meprin a (a) and meprin b (b), Numbers display position of
amino acid in full-length protein. Confirmed cleavage sites in the protein and identified in more than one secretome (biological replicate) is
indicated in bold.
BMP-7 bone morphogenic protein 7, DKK-1 Dickkopf-related protein 1, FGF-19 fibroblast growth factor, IGFBP-3 insulin growth factor binding
protein 3, IGF insulin-like growth factor 1, MMP matrix metalloproteases, TIMP tissue inhibitor of metalloproteases.






Fig. 6 a IGFBP-3 identified by TAILS as a substrate for meprin a
and b with cleavage sites shown. b A shift from 38 kDa to 22 kDa
and 18 kDa in processed IGFBP-3 by meprin a and b was demon-
strated by western blotting. Molecular masses are higher than their
theoretical sizes as indicated by curly braces due to three glycosyl-
ation sites at Asn116, Asn136, and Asn199. The sizes of the meprin
b-mediated fragments match those expected from the TAILS
proteomics data while for meprin a only one cleavage event was
detected. c Syndecan-4 was identified by TAILS as a substrate for
meprin a and b. d Time-dependent processing of syndecan-4 by
meprin b revealed a specific cleavage pattern using an antibody for
western blotting directed to the His-tag. Cleavage by meprin a
resulted in degradation of full-length syndecan-4. e Biochemical
validation of stratifin as a meprin substrate. f After incubation of
recombinant stratifin with meprin a and b, cleavage fragments were
transferred to a PVDF membrane and visualized after western blotting
with a specific stratifin antibody. The sizes of the cleavage products
derived from meprin a and b both matched those expected from the
TAILS sequence data. g The processed 23-kDa meprin b fragment
was subjected to Edman sequencing and confirmed the TAILS-
determined cleavage site exactly
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syndrome, in which meprin a is also detected in the
stratum granulosum, proteolytic interaction with PAI-2
might contribute to the progression of this hyperprolifer-
ative condition.
Two members of the trappin family, SLPI and elafin,
and LEKTI are present in human epidermis and may inhibit
the serine protease KLK7 to control downstream proteo-
lytic cascades [82]. Interestingly, SLPI is cleaved at the
Leu-Met bond, which is critical for inhibitory activity, but
we one found first for MMP14 at this same site in SLPI,
revealing a common control point in serine protease
activity by metalloprotease inactivation of a serine protease
inhibitor [55]. Dysfunction of the KLK7 inhibitors medi-
ated by meprins might lead to increased degradation of
desmoglein-1 and subsequently enhanced desquamation of
the skin. Moreover, zymogenic proKLK7 was also identi-
fied as a meprin substrate, where cleavage occurred two
amino acids N-terminal from the activation site (Online
resource 4). Recently, we have shown that this primary
meprin b-mediated processing results in accelerated acti-
vation of proKLK7 [83].
To close a feedback circle, meprin b-mediated
ADAM10 activation might also be important for skin
homeostasis, since it has been demonstrated that ADAM10
activity is essential for epidermal integrity [30]. Thus,
dysregulated meprin activity, due to expression, activation,
shedding or inhibition, would lead to altered activities of
ADAM10, KLK7 and LEKTI, which are all important for
skin homeostasis. Thus, our proteomic analyses and bio-
chemical studies have provided several new insights into
the biological role of meprins in skin that we are presently
investigating further.
Both meprin a and meprin b process growth factors,
cytokines and hormones [12, 84–86]. Meprin b activates
the cytokine IL-18 in mice, cleaving between Asn51 and
Asp52 [10]. TAILS also showed cleavage of human IL-18
at position Phe66/Glu67 (Table 3), confirming the findings
of the previous studies. Among the identified growth factor
Table 4 Candidate substrates
from the extracellular matrix for
meprin a and b identified by
TAILS
Protein samples were collected
as indicated in Table 1. Except
for laminin 5 and the APP,
which are known substrates and
were also identified by TAILS,
the other substrates presented
are new candidates for meprin
metalloproteases. Proteins in
italic have been further
validated in vivo (Online
resource 3). Sequences are
given in the one letter codes.
Arrows indicate the cleavage
sites analyzed by MS/MS for
meprin a (a) and meprin b (b).
Numbers display position of
amino acid in full-length
protein. Confirmed cleavage





h3, AD Alzheimer0s disease.
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substrates, of particular interest is VEGF-A (Online
resource 3). Morpholino knockdown of meprin a in zeb-
rafish embryos has revealed that this protease plays an
important role in the correct formation of the vascular
system [12] (Hedrich et al., in preparation). In developing
organisms, VEGF165-A plays a major role in angiogenesis
and is coexpressed with connective tissue growth factor
(CTGF). Immobilization of VEGF165-A by complexing
with CTGF results in antiangiogenic effects since VEGF-A
is prevented from binding to its receptor [87]. However,
MMP1 and MMP7, identified here as meprin substrates
(Table 1) (Online resource 4), are able to process CTGF
complexed with VEGF-A leading to the recovery of
VEGF165-A angiogenic activity [87, 88]. Meprin a and b
process not only MMPs but also CTGF itself (Table 3).
Whether cleavage occurs when CTGF is bound in a com-
plex remains to be elucidated, but a study analyzing
porcine uterine fluids [89] has demonstrated CTGF
cleavage products starting with the same N-terminus
(Asp186) as we identified for meprin a and b.
In conclusion, we present data that led to the identifica-
tion of important novel targets for the metalloproteases
meprin a and b based on a substrate screen of the entire
proteome (Fig. 7). Among the 151 identified extracellular
substrates, the findings of activation of several protease
zymogens and the inactivation of protease inhibitors reveal
that meprins are important nodes in the protease web. Such
modifications to the protease web also modify substrate
processing in vivo [21–23]. While this renders interpreta-
tion of findings from protease knockout mice difficult, and
indicates the need for further experimentation to discrimi-
nate direct from indirect effects, the very large number of in
vitro validations performed here by TAILS analysis (that
were exactly backed up by Edman degradation analysis of
meprin cleavage sites in several substrates) confirmed
that many of the meprin substrates found are of direct
Table 5 Other substrates for
meprin a and b identified by
TAILS
Substrates shown here have not
been further biochemically
validated. Sequences are given
in the one letter code. Arrows
indicate the cleavage sites
analyzed by MS/MS for
meprin a (a) and meprin b (b).
Numbers display position of
amino acids in full-length
proteins. Confirmed cleavage
sites in the protein and identified
in more than one secretome
(biological replicate) are
indicated in bold.
HSP heat-shock protein, HLA-A
HLA class I histocompatibility




SPARC secreted protein acidic
and rich in cysteine, LTBP
latent-transforming growth
factor b-binding protein.
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biological relevance. This new understanding of meprin
substrates indicates important and unexpected new biolog-
ical roles played by meprins. This, together with knowledge
of their substrate degradomes, are important steps in the
understanding of related pathological conditions, and sub-
sequently also important for drug development.
Fig. 7 Cleavage of meprin substrates influencing the protease web. The schemes illustrate several substrates of meprin a and b identified by
TAILS and show predicted in vivo roles when the substrates are proteolytically processed
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